Real-World asthma biologic use under the microscope in china

NCT ID NCT06605885

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study follows 202 Chinese asthma patients who are already prescribed biologic medications. Researchers will track how consistently patients take their biologics over 52 weeks and describe treatment patterns. No new drug is being tested; the goal is to gather real-world data on biologic use and outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Research Site

Hohhot, China, China
Research Site

Beijing, China
Research Site

Changsha, China
Research Site

Chengdu, China
Research Site

Foshan, China
Research Site

Fuzhou, China
Research Site

Guangzhou, China
Research Site

Hangzhou, China
Research Site

Hefei, China
Research Site

Jinan, China
Research Site

Kunming, China
Research Site

Nanchang, China
Research Site

Nanjing, China
Research Site

Ningbo, China
Research Site

Qingdao, China
Research Site

Quanzhou, China
Research Site

Shanghai, China
Research Site

Shenyang, China
Research Site

Shenzhen, China
Research Site

Shijiazhuang, China
Research Site

Suining, China
Research Site

Taiyuan, China
Research Site

Tianjin, China
Research Site

Ürümqi, China
Research Site

Wenzhou, China
Research Site

Wuhan, China
Research Site

Wuxi, China
Research Site

Xi'an, China
Research Site

Zhengzhou, China
Research Site

Zhuhai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.